Novocure starts mid-stage study of electric field therapy for brain cancer

Novocure (NVCR +5.6%) has enrolled first patient in its Phase 2 pivotal (EF-33) trial of Tumor Treating Fields delivered utilizing high-intensity arrays in patients with recurrent glioblastoma (GBM).

Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division.

The 25-patient trial will test potential incremental survival benefit of Tumor Treating Fields delivered at 200 kHz to the brain using high-intensity arrays.

The primary endpoint is progression free survival, and final data is expected in 2022.

https://seekingalpha.com/news/3593642-novocure-initiates-mid-stage-study-of-electric-field-based-therapy-for-brain-cancer